Overall survival benefit for weekly vs. three-weekly taxanes regimens in advanced breast cancer: A meta-analysis.
about
Taxane-containing regimens for metastatic breast cancerA Review of Systemic Treatment in Metastatic Triple-Negative Breast CancerChemotherapy-induced peripheral neurotoxicity: a critical analysisEffects on quality of life, anti-cancer responses, breast conserving surgery and survival with neoadjuvant docetaxel: a randomised study of sequential weekly versus three-weekly docetaxel following neoadjuvant doxorubicin and cyclophosphamide in womThe efficacy of taxane chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers.Randomised phase 3 open-label trial of first-line treatment with gemcitabine in association with docetaxel or paclitaxel in women with metastatic breast cancer: a comparison of different schedules and treatments.Phase I study of OM-174, a lipid A analogue, with assessment of immunological response, in patients with refractory solid tumorsTumor-Specific Systemic Treatment in Advanced Breast Cancer - How Long does it Make Sense?Weekly gemcitabine and docetaxel in refractory soft tissue sarcoma: a retrospective analysis.Current approaches to the management of Her2-negative metastatic breast cancer.Taxanes for the treatment of metastatic breast cancer.Dose modifications in Asian cancer patients with hepatic dysfunction receiving weekly docetaxel: A prospective pharmacokinetic and safety study.Phase I study of the safety and pharmacokinetics of trabectedin with docetaxel in patients with advanced malignanciesWeekly versus three weeks chemotherapy for advanced ovarian cancer: a meta-analysis.Chemotherapy-induced peripheral neuropathy in adults: a comprehensive update of the literature.Dysregulation of signaling pathways associated with innate antibacterial immunity in patients with pancreatic cancer.Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology Clinical Practice Guideline.Kinetic-Pharmacodynamic Model of Chemotherapy-Induced Peripheral Neuropathy in Patients with Metastatic Breast Cancer Treated with Paclitaxel, Nab-Paclitaxel, or Ixabepilone: CALGB 40502 (Alliance).Current challenges of metastatic breast cancer.Incidence and risk of peripheral neuropathy with nab-paclitaxel in patients with cancer: a meta-analysis.Incidence of taxane-induced peripheral neuropathy receiving treatment and prescription patterns in patients with breast cancer.Ritonavir inhibits intratumoral docetaxel metabolism and enhances docetaxel antitumor activity in an immunocompetent mouse breast cancer model.Gene expression disorders of innate antibacterial signaling pathway in pancreatic cancer patients: implications for leukocyte dysfunction and tumor progressionWeekly paclitaxel in escalating doses in a patient with anthracycline-resistant, triple-negative, metastatic breast cancer with severe liver dysfunction.Taxane-Induced Peripheral Neurotoxicity.Antitumor activity and safety profile of weekly carboplatin plus paclitaxel in metastatic breast cancer: a ten-year, monocentric, retrospective study.A phase II study of metronomic paclitaxel/cyclophosphamide/capecitabine followed by 5-fluorouracil/epirubicin/cyclophosphamide as preoperative chemotherapy for triple-negative or low hormone receptor expressing/HER2-negative primary breast cancer.
P2860
Q24187214-350D7072-6ADB-400C-B4EE-8FB3627B6FC8Q26752846-79BFBBDB-696E-4427-9673-60B6AEAAA9F2Q27010318-56EBA668-5289-478B-B761-58CBDB9BF495Q33904763-B20FB242-7E5F-471B-8BB0-09AAA42E8996Q33962070-C3C31DFF-71A9-4404-9676-512E32B93A98Q34640591-ACCFC899-4C30-4CBB-AF37-C44B1B53B051Q34644769-62EC8B65-0EF5-4965-89E9-70B41103988BQ34870267-6EA878A0-6461-4619-BB55-997580BF3E16Q35877763-593B12D6-6C98-4C80-B6C8-960D8E7E702DQ36245461-B686C51F-FA1B-4130-927D-07F942C417B7Q36364762-D7F2ADA2-A5BA-4400-AEC1-F73CD7342355Q36622084-9B4997C2-D868-4F64-AAE5-AD3F8344C14FQ37163139-B10CCF53-3DB7-4103-9654-0B0F093ADFC3Q37629090-1E370AAB-0D3B-4A21-8994-01CF47C307B3Q37659699-44E354C2-DA1F-4495-85F6-C1D4BE186686Q37739809-0DAA45CF-81C5-4516-86ED-F87BCA615124Q38245797-15EB74C6-C051-483D-B761-3DDCB89721C7Q38722948-EB52EACF-634E-479A-B4A5-DAB816A619D6Q38785362-A7831C66-DA56-4025-A323-D071FDCE5148Q38946259-287D7EDC-C26C-42D7-AE7C-42E8EF58F81CQ39138091-52AE07B8-E4D8-46B8-9861-3F58334695D7Q40617502-A71C5B37-9400-4585-B158-D29B6CDCC4ABQ40923346-E3211C12-EF0B-4382-92C6-1475333869E6Q42413022-96CDEF56-F4F0-425E-906E-82973DDF994EQ45759415-91A66BBD-6472-4D3B-9A3A-7180D005AEC9Q48274719-0AB82E28-6C4E-43AC-AD6B-9A4692738776Q54349347-B0797B86-598B-4599-9BF0-416AF0E8D952
P2860
Overall survival benefit for weekly vs. three-weekly taxanes regimens in advanced breast cancer: A meta-analysis.
description
2009 nî lūn-bûn
@nan
2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Overall survival benefit for w ...... reast cancer: A meta-analysis.
@ast
Overall survival benefit for w ...... reast cancer: A meta-analysis.
@en
type
label
Overall survival benefit for w ...... reast cancer: A meta-analysis.
@ast
Overall survival benefit for w ...... reast cancer: A meta-analysis.
@en
prefLabel
Overall survival benefit for w ...... reast cancer: A meta-analysis.
@ast
Overall survival benefit for w ...... reast cancer: A meta-analysis.
@en
P2093
P1476
Overall survival benefit for w ...... reast cancer: A meta-analysis.
@en
P2093
Antonis Valachis
Davide Mauri
Ioanna Karathanasi
Konstantinos Kamposioras
Lamprini Tsali
Magdalini Bristianou
Nikolaos P Polyzos
P356
10.1016/J.CTRV.2009.10.006
P577
2009-11-27T00:00:00Z